AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27173100
Drug: Warfarin (CYP2C9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (CYP2C9 interacting drugs)
Trial: 27173100
Drug: Warfarin (mechanical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (mechanical heart valves)
Trial: 27173100
Drug: Warfarin (CYP2C9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (CYP2C9 variant allele)
Trial: 24997182
Drug: sham injections
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sham injections
Trial: 15753241
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg lorazepam
Trial: 12767566
Drug: Lycopene (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lycopene (2 mg twice daily)
Trial: 8892714
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg of NA and 1 microg of EE2
Trial: 8892714
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of NA and 2.5 microg of EE2
Trial: 8892714
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of NA and 5 microg of EE2
Trial: 8892714
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of NA and 10 microg of EE2
Trial: 8892714
Drug: NA-EE2 treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NA-EE2 treatments
Trial: 1676825
Drug: British group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: British group (unrestricted prescribing of H2-receptor antagonists)
Trial: 1676825
Drug: Australian group
RxNorm normalized name: Australian pine pollen extract
DrugBank: Casuarina equisetifolia pollen (DB10485)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Australian group (H2-receptor antagonists allowed only after gastroscopy or barium meal)
Trial: 21636735
Drug: Exercise +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise + Supplement (E + S) with 70 g of honey
Trial: 21636735
Drug: Exercise (E)
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise (E) with 70 g of artificial sweetener
Trial: 17331388
Drug: Tulobuterol tablet
RxNorm normalized name: tulobuterol
DrugBank: Tulobuterol (DB12248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tulobuterol tablet
Trial: 2620671
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg p.o. (n = 21)
Trial: 2620671
Drug: Ciprofloxacin 200
RxNorm normalized name: ciprofloxacin 200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 200 mg i.v. over 30 min (n = 15)
Trial: 29687650
Drug: Weight loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight loss plus whey protein supplementation (total protein: 1.2 g/kg/d)
Trial: 29687650
Drug: Weight loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight loss and the recommended daily allowance for protein (0.8 g/kg/d)
Trial: 20185805
Drug: Anemic residents
RxNorm normalized name: IRON 100 mg in 1 mL INTRAMUSCULAR INJECTION [ANEM-X 100]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anemic residents treated with at least one medication
Trial: 18206569
Drug: Tai Chi
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai Chi Chuan (TCC) exercises; specific dosage and duration not mentioned.
Trial: 11121996
Drug: Sildenafil (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (25 mg, 50 mg, 100 mg)
Trial: 9772138
Drug: High-energy supplement
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-energy supplement (HES) 2.14 MJ/d
Trial: 9772138
Drug: Low-energy supplement
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy supplement (LES) 0.50 MJ/d
Trial: 9772138
Drug: High-energy supplement
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-energy supplement (HES)
Trial: 9772138
Drug: Low-energy supplement
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy supplement (LES)
Trial: 7876659
Drug: Contrast echocardiography
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast echocardiography with 200 mg/ml and 400 mg/ml SHU 508A intravenously
Trial: 3207375
Drug: Intravenous pulsed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pulsed methylprednisolone
Trial: 1105833
Drug: Neomycin-erythromycin combination
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neomycin-erythromycin combination (3 gm of each, day preoperatively, plus mechanical cleansing)
Trial: 1105833
Drug: Other preparations
RxNorm normalized name: other preparations, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other preparations
Trial: 28081990
Drug: Standard volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard volume local anesthetic administered (Group S, n=30)
Trial: 28081990
Drug: Low volume
RxNorm normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low volume anesthetic administered (Group L, n=30)
Trial: 28081990
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Group L and Group S)
Trial: 11445475
Drug: Anterior vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior vaginal wall suspension for urethral hypermobility (UH group)
Trial: 9860150
Drug: L-NAME 1
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NAME 1 mg x kg(‐1) x h(‐1) for 12 hours
Trial: 3051839
Drug: Transdermal scopolamine
RxNorm normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal scopolamine (TS) adhesive, delivering 140 micrograms initially and 5 micrograms/h thereafter
Trial: 3051839
Drug: Droperidol (DHBP)
RxNorm normalized name: Droperidol
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Droperidol (DHBP) 0.5 ml (1.25 mg) i.v.
Trial: 3051839
Drug: Placebo (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.5 ml i.v.)
Trial: 8919900
Drug: Transdermal scopolamine
RxNorm normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal scopolamine (TS)
Trial: 28634136
Drug: Pinaverium (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinaverium (50 mg tablets, 3 times daily for 4 weeks)
Trial: 23144445
Drug: Cindunistat 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cindunistat 50 mg/day
Trial: 23144445
Drug: Cindunistat 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cindunistat 200 mg/day
Trial: 23144445
Drug: Cindunistat (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cindunistat (50 or 200 mg/day)
Trial: 16945898
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri ATCC 55730 via straw (200 ml of water through a prepared straw once daily for 3 weeks)
Trial: 16945898
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri ATCC 55730 via tablet (one tablet once daily for 3 weeks)
Trial: 16945898
Drug: Placebo straw
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo straw (200 ml of water through a placebo straw once daily for 3 weeks)
Trial: 16945898
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet (one placebo tablet once daily for 3 weeks)
Trial: 14705152
Drug: Fluoxetine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine plus nutritional supplements
Trial: 14705152
Drug: Fluoxetine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine plus nutritional placebo
Trial: 8204245
Drug: Nicardipine 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 1 mg
Trial: 3294914
Drug: Listerine mouthrinse
RxNorm normalized name: Listerine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Listerine mouthrinse (20 ml for 30 s, twice daily)
Trial: 3294914
Drug: Chlorhexidine mouthrinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine mouthrinse (0.2% or 0.1% solution, 10 ml for 60 s, twice daily)
Trial: 3294914
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (20 ml mouthrinse for 30 s, twice daily)
Trial: 25476072
Drug: Outreach-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outreach-based treatment
Trial: 20207664
Drug: Treatment effects
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment effects related to smoking cessation
Trial: 20207664
Drug: Treatment effects
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment effects related to diet
Trial: 20207664
Drug: Treatment effects
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment effects related to sun exposure
Trial: 2149051
Drug: Ciprofloxacin (monotherapy)
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (monotherapy)
Trial: 16995327
Drug: Metoprolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (50 mg)
Trial: 28534225
Drug: Controlled dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled dietary acrylamide intake via coffee (0.15-0.17 µg/kg bw) and a meal (14.1-15.9 µg/kg bw) on days 6 and 10 respectively.
Trial: 28534225
Drug: Controlled dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled dietary acrylamide minimized diet (0.05-0.06 µg/kg bw) throughout the 13-day study period.
Trial: 28534225
Drug: Ingestion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of 13C3D3-AA (1 µg/kg bw) on day 6.
Trial: 25400681
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 2000 IU once daily
Trial: 8080348
Drug: Yohimbine hydrochloride,
RxNorm normalized name: Yohimbine Hydrochloride, 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine hydrochloride, 0.4 mg/kg
Trial: 10613225
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (rHuEPO), 6000 U i.v. twice weekly for 3 weeks
Trial: 7261552
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg b.i.d.)
Trial: 29153938
Drug: Tribendimidine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tribendimidine (200 mg for children, 400 mg for adolescents and adults)
Trial: 29153938
Drug: Praziquantel (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (50 mg/kg bodyweight and 25 mg/kg bodyweight, 6 h apart)
Trial: 26768923
Drug: Nitrous oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrous oxide (N2O) 65% in oxygen (O2) via mask, flow of 10 L/min
Trial: 26768923
Drug: Oxygen (O2)
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxygen (O2) only, flow of 10 L/min (control group)
Trial: 15389231
Drug: Ezetimibe (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe (10 mg/day) plus atorvastatin (10 mg/day, titrated to 40 mg/day if needed)
Trial: 15389231
Drug: Atorvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (10 mg/day, titrated to 80 mg/day if needed)
Trial: 7722120
Drug: Candoxatrilat 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candoxatrilat 200 mg
Trial: 2024791
Drug: Metaproterenol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaproterenol (15 mg by nebulizer)
Trial: 2024791
Drug: Atropine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (1.5 mg by nebulizer)
Trial: 24824633
Drug: Vildagliptin 50
RxNorm normalized name: vildagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin 50 mg twice a day
Trial: 17571092
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (treatment deferred to normal waiting list, received three home visits)
Trial: 15519028
Drug: Caffeine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (200 mg, equivalent to 2 cups of coffee)
Trial: 1771604
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (800 micrograms twice daily)
Trial: 30771791
Drug: Mitochondrial agents,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitochondrial agents, N-acetylcysteine
Trial: 26396135
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of ALC hydrochloride 590 mg
Trial: 26396135
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of ALC hydrochloride 590 mg
Trial: 11444885
Drug: Subcutaneous carbon-dioxide
RxNorm normalized name: Carbon Dioxide
DrugBank: Carbon dioxide (DB09157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous carbon-dioxide insufflations (10 treatments) and standard physical treatment
Trial: 11444885
Drug: Standard physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard physical treatment only
Trial: 8111939
Drug: Decubitus position
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decubitus position for 30 min after epidural blood patch
Trial: 8111939
Drug: Decubitus position
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decubitus position for 60 min after epidural blood patch
Trial: 8111939
Drug: Decubitus position
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decubitus position for 120 min after epidural blood patch
Trial: 3207854
Drug: ibuprofen SR
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ibuprofen SR 800 mg
Trial: 3207854
Drug: ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine 300 mg followed by ibuprofen SR 800 mg
Trial: 3207854
Drug: conventional ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: conventional ibuprofen tablets (2 x 400 mg)
Trial: 12708395
Drug: Netilmycin in
RxNorm normalized name: Netilmycin
DrugBank: Netilmicin (DB00955)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Netilmycin in combination with Cefasolin
Trial: 12708395
Drug: Gentamycin in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamycin in combination with Cefasolin
Trial: 11885180
Drug: Mobile implants
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile implants at placement
Trial: 11885180
Drug: Non-mobile implants
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-mobile implants at placement
Trial: 11885180
Drug: HA-coated implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA-coated implants (mobile at placement)
Trial: 11885180
Drug: Non-HA-coated implants
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-HA-coated implants (mobile at placement)
Trial: 11885180
Drug: HA-coated implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA-coated implants (non-mobile at placement)
Trial: 11885180
Drug: Non-HA-coated implants
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-HA-coated implants (non-mobile at placement)
Trial: 1421911
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily dose of 4 mg/kg of trimethoprim coupled with 17.5 mg/kg of sulphadiazine for 3 days (group 1)
Trial: 1421911
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily dose of 4 mg/kg of trimethoprim coupled with 17.5 mg/kg of sulphadiazine for 10 days (group 2)
Trial: 3880875
Drug: Allopurinol and
RxNorm normalized name: Allopurinol and lesinurad only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol and adenine therapy
Trial: 30914464
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (BV) in combination with cyclophosphamide, doxorubicin, and prednisone (CHP)
Trial: 15119909
Drug: Extended-release carbamazepine
RxNorm normalized name: carbamazepine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release carbamazepine (ERC-CBZ)
Trial: 10638770
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide pulse therapy (750 mg/m2) for 12 months; concurrent prednisone (10 mg/day)
Trial: 10638770
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide (2-2.5 mg/kg/day) for 12 months; concurrent prednisone (10 mg/day)
Trial: 7781174
Drug: PGE2 vaginal
RxNorm normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PGE2 vaginal gel every 12 hours, initial dose of 2 mg followed by two additional doses at 12 hour intervals if not in active labor.
Trial: 7781174
Drug: PGE2 vaginal
RxNorm normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PGE2 vaginal gel every 6 hours, initial dose of 1 mg followed by 2 mg at 6 hour intervals for a maximum of two additional doses if not in active labor.
Trial: 7781174
Drug: PGE2 vaginal
RxNorm normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PGE2 vaginal gel every 12 hours
Trial: 7781174
Drug: PGE2 vaginal
RxNorm normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PGE2 vaginal gel every 6 hours
Trial: 1969770
Drug: Succinylcholine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 1.5 mg.kg‐1 after d-tubocurarine 0.05 mg.kg‐1, intubation after 60 seconds
Trial: 1969770
Drug: Succinylcholine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 1.5 mg.kg‐1 after d-tubocurarine 0.05 mg.kg‐1, intubation after 90 seconds
Trial: 1969770
Drug: Vecuronium 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.01 mg.kg‐1 followed by 0.1 mg.kg‐1, intubation after 60 seconds
Trial: 1969770
Drug: Vecuronium 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.01 mg.kg‐1 followed by 0.1 mg.kg‐1, intubation after 90 seconds
Trial: 23286246
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day palmvitee supplementation
Trial: 22120944
Drug: Topical oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical oxytocin gel for seven days
Trial: 22120944
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel for seven days
Trial: 22120944
Drug: Topical oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical oxytocin gel
Trial: 19480654
Drug: Cholecalciferol (vitamin
RxNorm normalized name: cholecalciferol (vitamin D3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (vitamin D3) 6800 International Units daily for one year
Trial: 15496221
Drug: Thioridazine 50
RxNorm normalized name: thioridazine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thioridazine 50 mg with donepezil 5 mg daily for 2 weeks
Trial: 12536625
Drug: Captopril (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (1 mg.kg‐1, oral) pretreatment 48 hours before operation
Trial: 8024908
Drug: ketorolac 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketorolac 0.75 mg kg‐1 i.v.
Trial: 8024908
Drug: morphine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 0.1 mg kg‐1 i.v. and metoclopramide 0.15 mg kg‐1
Trial: 2811970
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of lithium (serum concentration 0.8 to 1.0 mmol per liter)
Trial: 2811970
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of lithium (serum concentration 0.4 to 0.6 mmol per liter)
Trial: 825780
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (surgery followed by chemotherapy, second-look laparotomy, and subsequent whole abdominal radiation)